Pro Medicus Limited (ASX: PME) has secured a five-year, $37 million contract renewal with Northwestern Medicine, featuring increased minimum spend and higher fees per transaction.
The deal is the second consecutive five-year agreement between the two organisations, building directly on a relationship that began when Northwestern Medicine first standardised on the Visage 7 imaging platform.
What the Northwestern Medicine Renewal Covers
The renewed agreement is with Northwestern Medicine, a leading academic health system in Chicago, serving over 200 sites. The contract not only increases the minimum transaction volume but also raises the fee paid to Pro Medicus for each exam, reflecting growth since the initial agreement.
That is a meaningful shift from a standard like-for-like rollover. Both the price per examination and the committed volume floor have moved upward, which means the contract is worth more to Pro Medicus before any additional growth kicks in.
The original deal, signed in June 2020, was valued at A$22 million. The new agreement comes in at $37 million, a roughly 68 per cent increase in contract value over the same five-year term.
This contract builds on Pro Medicus’s strong client retention track record. The company’s Visage 7 Viewer platform is now firmly established within Northwestern Medicine, supporting both financial and clinical outcomes.
The Visage 7 platform underpins Pro Medicus’s contract relationships with leading US academic medical centres. [Pro Medicus]
What CEO Dr Sam Hupert Said
Pro Medicus chief executive Dr Sam Hupert did not shy away from the significance of the terms.
“We are extremely pleased that in addition to committing to a second five-year term at an increased fee per exam, NM have also committed to an increase in their minimums reflecting the growth in their exam volumes since standardising on our platform five years ago,“ he said.
The comment cuts to the core of what makes this renewal different from a simple contract extension. Northwestern Medicine is not just staying on the platform. It is paying more, and committing to more volume. That reflects genuine operational dependency on Visage 7.
Part of a Bigger Renewal Run
Pro Medicus continues to invest in its core imaging platform and grow its base of recurring contract revenue. Management highlighted almost $80 million in recent renewals, supporting the company’s belief in the lasting value of its technology.
That figure is worth sitting with. Close to $80 million in renewals secured in under a month points to a company whose existing clients are not just staying but staying on better terms.
Pro Medicus generates nearly all of its revenue through transaction-based contracts tied to examination volumes. There is no hardware or cloud infrastructure cost for the company when volumes grow. Revenue scales, but costs largely do not. That model is what makes renewals like this one more valuable than they appear on paper.
The company’s record HY26 results told a similar story. Revenue climbed 28.4 per cent to $124.8 million in the December 2025 half, while profit after tax surged 230.9 per cent to $171.2 million. Forward revenue projections sat above $1.08 billion over five years, assuming key contract renewals. This deal is one of them.
Northwestern Medicine: A High-Stakes Client
Northwestern Medicine is not a fringe customer. It operates more than 200 sites across Illinois and is consistently ranked among the top academic health systems in the United States.
Standardising across a network that size means Pro Medicus’s Visage 7 platform is processing enormous volumes of imaging data daily. A renewal on improved terms from a client of this scale is a commercial signal that the platform is delivering measurable value, not just functional adequacy.
Pro Medicus now serves 11 of the top 20 US hospitals as ranked by US News for 2024-2025. Northwestern Medicine sits firmly in that elite group. Each renewal at this level adds weight to the company’s position when negotiating with new prospects.
PME Share Price
The PME share price has pulled back significantly from its all-time high of $336.00 reached in July 2025. The stock most recently traded around $133, against a 52-week range of $107.75 to $336.00. Over the past 12 months, Pro Medicus shares have declined 40%, trailing the S&P/ASX 200 Index, which has risen 16% over the same period.
PME Price Chart [ASX]
Investors watching the stock will want to verify the current price directly on the ASX before making any decisions, as data moves quickly on announcement days.
Also Read: Fortescue Boss Calls Mining Lobby’s Fuel Tax Push “Absolutely Ridiculous”
FAQ
Q: What is the Pro Medicus Northwestern Medicine contract renewal worth?
A: The renewed contract is valued at $37 million over five years. The original 2020 deal was worth $22 million over the same term.
Q: Why is the Pro Medicus and Northwestern Medicine deal significant?
A: The renewal includes both a higher fee per examination and increased minimum volume commitments. This means Pro Medicus earns more from the same client base, without additional infrastructure costs.
Q: What is Pro Medicus’s Visage 7 platform?
A: Visage 7 is Pro Medicus’s cloud-based medical imaging and visualisation software used by radiologists, clinicians, and physicians to view and interpret 2D, 3D, and 4D medical images. It is deployed across major US, Australian, and European hospitals.
Q: How many major US hospitals does Pro Medicus serve?
A: Pro Medicus serves 11 of the top 20 US hospitals as ranked by US News for 2024-2025, including Duke Health, Mayo Clinic, NYU Langone Health, and Northwestern Medicine.
Q: Is Pro Medicus a buy right now?
A: This is not financial advice. Investors should assess PME’s current valuation, revenue model, and growth pipeline against their own risk tolerance. Speaking to a licensed financial adviser is recommended before making any investment decisions.
Disclaimer: This article is for informational purposes only and does not constitute financial product advice. Past performance is not a reliable indicator of future performance. Always consider your personal financial situation and consult a licensed financial adviser before investing.
Source:
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-03077965-3A691177
Tags: ASX: PME, Pro Medicus Last modified: April 13, 2026
